Aspirin plus atorvastatin for advanced, treatment-resistant prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial studies whether daily aspirin and atorvastatin can slow advanced prostate cancer that has continued to grow despite hormone therapy. It may help by reducing cancer growth and inflammation, but you would need to meet several specific safety and medication rules.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have prostate cancer confirmed by biopsy, and doctors do not think curative local treatment is possible
- Your prostate cancer is “castrate-resistant,” meaning it kept progressing while your testosterone was kept very low on hormone therapy
- Your cancer may be spread to other parts of the body (metastatic or non-metastatic) based on scans
- You are generally well enough to do usual activities (performance status 0–2) and are expected to live at least 6 months
- You have not taken key life-prolonging CRPC medicines before (like enzalutamide, abiraterone, docetaxel, cabazitaxel, radium-223, or sipuleucel-T)
- You can take these study pills safely: kidney function is adequate, liver tests are not too high, and you’re not already taking aspirin or a statin daily
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial tests the blood pressure medication telmisartan in men with prostate cancer who are already on a stable treatment and not needing an immediate change. The goal is to see if adding telmisartan can help control the cancer without extra side effects.
This trial tests if adding docetaxel chemotherapy helps men whose PSA hasn't dropped enough after at least 6 months of standard hormone therapy (ADT) plus an ARPI pill (like abiraterone or enzalutamide) for metastatic prostate cancer that still responds to hormones.
This trial tests a shorter course of hormone therapy plus targeted radiation for prostate cancer that has spread to a few spots (oligometastatic). The goal is to see if less hormone therapy can still control the cancer effectively.
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
This trial tests a combination of two drugs—disitamab vedotin (a targeted antibody-drug that attacks HER2-positive cancer cells) and abiraterone (a hormone therapy)—to see if they can slow or shrink prostate cancer that has spread and become resistant to standard treatments.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.